Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: A multicenter study

Widespread antimony resistance renders conventional amphotericin B the only option for the treatment of visceral leishmaniasis (VL) in North Bihar, India. Because of its excellent safety profile, a large dose (7.5 mg/ kg) of liposomal amphotericin B (L-AmB) was given to each of 203 patients with VL at 4 treatment centers, and the patients were discharged the next day. At initial clinical and parasitological follow-up, performed on day 30 after treatment, evidence of a cure was seen in 195 (96%) of 203 patients (95% CI, 92 - 98); 4 patients experienced treatment failure. Two patients were lost to follow-up, 2 died ( one due to progressive disease and another, 5 months after treatment, due to an unrelated illness), and 12 experienced relapses during follow-up. Thus, 183 patients (90%; 95% CI, 85 - 94) had obtained final cure 6 months after treatment. Very few adverse events ( fever with rigor, in 9.8% of patients) were seen. Single-dose L-AmB ( 7.5 mg/ kg) treatment is safe and effective, and it may be used for the mass treatment of VL in India.